GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Inc (ROCO:6892) » Definitions » Notes Receivable

Taiwan Bio Therapeutics (ROCO:6892) Notes Receivable : NT$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Notes Receivable?

Taiwan Bio Therapeutics's Notes Receivable for the quarter that ended in Dec. 2024 was NT$0.00 Mil.


Taiwan Bio Therapeutics Notes Receivable Historical Data

The historical data trend for Taiwan Bio Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Notes Receivable Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Taiwan Bio Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Taiwan Bio Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.

Taiwan Bio Therapeutics Headlines

No Headlines